Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
02.06. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.06.2025 | 552 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.06.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.06.2025ISIN NameCA19243C1005 COGNETIVITY... ► Artikel lesen | |
26.05. | Delisting of Lipidor AB from Nasdaq First North Growth Market | 230 | GlobeNewswire | On May 26, 2025, Lipidor AB was declared bankrupt by the Stockholm District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist... ► Artikel lesen | |
26.05. | XFRA L7R: AUSSETZUNG/SUSPENSION | 117 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLIPIDOR AB L7R SE0012558617... ► Artikel lesen | |
26.05. | Suspension of Trading in Lipidor AB at FNSE | 175 | GlobeNewswire | 2025-05-26T06:33:44Z
Suspension
At Trading Venue FNSE
Due to Non Disclosure Of
Inside Information About The Issuer Or Financial Instrument
Ongoing:
True
Comments: Nasdaq Stockholm has, to the extent... ► Artikel lesen | |
25.05. | Lipidor AB: Lipidor applies for bankruptcy | 223 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 25th May 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company's board has resolved to file for bankruptcy on behalf of the Company. The... ► Artikel lesen | |
24.05. | Lipidor AB: Lipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis | 114 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 24th May 2025 - (Nasdaq First North: LIPI) reports negative results from a Phase III clinical study of the AKP02G2 cutaneous spray for mild to moderate plaque psoriasis. The study... ► Artikel lesen | |
19.05. | Lipidor AB: Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2 | 131 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 19th May 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study of AKP02G2 for the treatment of psoriasis has reached... ► Artikel lesen | |
17.03. | Lipidor AB: Lipidor announces all patients enrolled in ongoing Phase III study | 152 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 17th March 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that all patients in the ongoing Phase III study for the drug candidate AKP02G2 have been... ► Artikel lesen | |
LIPIDOR Aktie jetzt für 0€ handeln | |||||
28.02. | Lipidor AB: Lipidor AB (publ) publishes year-end report for 2024 | 226 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 28th February 2025 - Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January - December 2024. The report is available... ► Artikel lesen | |
21.01. | Lipidor AB: Lipidor announces half of patients enrolled in ongoing Phase III study | 524 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 21st January 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that half of the patients in the ongoing Phase III study for the drug candidate AKP02G2... ► Artikel lesen | |
20.11.24 | Lipidor AB: Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025" | 159 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 20 November 2024 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today provides an update on the business from CEO Ola Holmlund, also announcing a company presentation... ► Artikel lesen | |
28.08.24 | Lipidor AB: Lipidor AB (publ) publishes interim report for Q2 2024 | 153 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 28 August 2024 - Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January - June 2024. The report is available on the... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ORAMED PHARMACEUTICALS | 1,779 | -1,25 % | Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical | Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology
Accelerating multiple late-stage cancer therapies... ► Artikel lesen | |
MEDMEN ENTERPRISES | - | - | This Week In Cannabis: The MedMen Saga, Multi-Million-Dollar Financings, Controversies In LatAm And More | ||
OPUS GENETICS | 0,893 | -2,72 % | Opus Genetics, Inc.: Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited... ► Artikel lesen | |
VERTICAL AEROSPACE | 4,400 | -1,79 % | Vertical Aerospace Provides First Half-Year 2025 Operating Update, Demonstrating Piloted Flight Test Progress and Supply Chain Maturity | Signs new long-term partnership with Aciturri Aerostructures to produce the entire airframe, including the wing, empennage, pylons and fuselage for the VX4
Piloted wingborne flight tests... ► Artikel lesen | |
BOIRON | 20,800 | 0,00 % | Boiron USA: Boiron's Camilia Tummy Receives Top Honors from Baby Innovation Awards | Newtown Square, Pennsylvania--(Newsfile Corp. - June 26, 2025) - Camilia Tummy® has received the "Baby Accessory Product of the Year" in the 2025 Baby Innovation Awards. Now in its fifth year, this... ► Artikel lesen | |
PACIRA BIOSCIENCES | 21,400 | 0,00 % | Pacira outlines narrowed $730M-$750M revenue guidance and increased margin targets as J&J ZILRETTA partnership takes shape | ||
RED LIGHT HOLLAND | 0,025 | 0,00 % | Red Light Holland Corp.: Red Light Holland CEO Todd Shapiro Invited by Blockchain Futurist Conference for Fireside Chat and Panel Hosting | Toronto, Ontario--(Newsfile Corp. - July 30, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the... ► Artikel lesen | |
INNOCARE PHARMA | 1,870 | -3,61 % | INNOCARE (09969): DATE OF BOARD MEETING | ||
PHIBRO ANIMAL HEALTH | 24,400 | +2,52 % | Dividendenbekanntmachungen (04.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADESSO SE DE000A0Z23Q5 - 0,75 EUR AGEAS SA/NV BE0974264930 - 2 EUR AIR LEASE CORPORATION US00912X3026 0,22 USD 0,1934 EUR ANALOG... ► Artikel lesen | |
BAYER | 25,960 | +0,97 % | Ihre wichtigsten Termine: Zahlenupdates von: Airbnb, McDonald's, Uber, Lyft, Walt Disney, Bayer & Zalando | © Foto: Christoph Schmidt/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00... ► Artikel lesen | |
MERCK KGAA | 111,05 | +2,82 % | Schwacher Dollar: Umsatz- und Ergebniseinbußen für Merck - Nochmals neue Ziele | DARMSTADT (dpa-AFX) - Die Dollar-Schwäche hat beim Darmstädter Merck-Konzern für ein unerwartet schwaches zweites Quartal gesorgt. Der Umsatz ging um knapp zwei Prozent auf 5,26 Milliarden Euro zurück... ► Artikel lesen | |
NOVO NORDISK | 42,835 | -0,40 % | Novo Nordisk-Aktie: Wann sollten Anleger zuschlagen? | Novo Nordisk-Aktien sind in den vergangenen Monaten extrem drastisch eingebrochen. Nachdem die Papiere noch im Vorjahr über 1.000 dänischen Kronen notiert haben, sind sie jetzt lediglich 300 dänische... ► Artikel lesen | |
ELI LILLY | 547,60 | +0,02 % | Eli Lilly zieht vorbei: Von Europas Darling zum Börsen-Drama: Wegovy kann Novo nicht retten | © Foto: Steffen Trumpf/dpaNovo Nordisk meldet zwar Rekordumsätze mit Wegovy, doch Prognosesenkungen, US-Konkurrenz und Nachahmer setzen den Dänen zu. Seit Juni 2024 sind über 400 Milliarden US-Dollar... ► Artikel lesen | |
TILRAY BRANDS | 0,867 | +9,77 % | Tilray Brands: +40% in einer Woche nach Kauftipp! | Erst letzte Woche habe ich dargelegt, weshalb ich die Aktie von Tilray Brands wieder für kaufenswert halte. Jetzt folgt mit politischem Rückenwind ein langersehnter Kurstreiber. Allein heute legt der... ► Artikel lesen | |
CANOPY GROWTH | 1,342 | -1,18 % | Märkte am Morgen: Bitcoin, Thyssen, Cancom, Glencore, Expedia, Under Armour, Canopy, BYD/Tesla | Der DAX hat sich am Freitag mit leichten Verlusten ins Wochenende verabschiedet. Trotzdem hat der deutsche Leitindex eine starke Woche hinter sich. Unter dem Strich ging es fast 3,2 Prozent nach oben.Auch... ► Artikel lesen |